Develops cell therapies for autoimmune diseases.
Jun 2026Revenue $1.48M/yrExpenses $157M/yr
No trendCash runway ≈ 1.9 years from Jun 2026
Figures by year
When will Cartesian Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.48M and expenses $157M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.80M | $146M | −$143M |
| Dec 2024 | $38.9M | $82.8M | −$43.9M |
| Dec 2023 | $26.0M | $112M | −$86.4M |
| Dec 2022 | $111M | $96.2M | $14.5M |
| Dec 2021 | $85.1M | $89.7M | −$4.60M |
| Dec 2020 | $16.6M | $73.4M | −$56.8M |
| Dec 2019 | $6.68M | $59.1M | −$52.5M |
| Dec 2018 | $903K | $65.9M | −$65.0M |
| Dec 2017 | $207K | $64.0M | −$63.8M |
| Dec 2016 | $8.08M | $42.8M | −$34.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.